Actively Recruiting
Exploratory Study Evaluating Safety and Preliminary Efficacy of IASO206 Injection in Adults With Relapsed or Refractory Multiple Myeloma
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2026-10-27
12
Participants Needed
1
Research Sites
95 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and preliminary effectiveness of IASO206 Injection, an in vivo CAR-T therapy, in patients with relapsed or refractory multiple myeloma who have undergone at least two prior treatments. This early exploratory clinical study focuses on individuals aged 18 to 75 years with measurable disease and BCMA expression on their myeloma cells. The study is sponsored by the Institute of Hematology & Blood Diseases Hospital in China. Participants will receive a single infusion of IASO206, a third-generation lentiviral vector carrying a BCMA-targeted CAR. The trial is designed as an open-label, single-arm study without a control group. The infusion is intended to target cancer cells expressing BCMA, and participants will be followed for up to two years after treatment to monitor outcomes. During the study, participants will be closely monitored for adverse events and various efficacy measures including overall response rate, time to response, MRD negativity rate, duration of response, progression-free survival, and overall survival. Additional assessments will include pharmacodynamic and pharmacokinetic analyses. Follow-up visits and evaluations will continue for up to two years post-infusion to assess safety and treatment effects over time.
CONDITIONS
Brief Title
IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here